Study

EFFICACY OF SSRIS IN TREATING BORDERLINE PERSONALITY DISORDER WITH MAJOR DEPRESSION.

Principal Investigator

Emil Coccaro, M.D., Michael McCloskey, Ph.D.

Description

The purpose of this study is to see how a type of medication called Selective Serotonin Reuptake Inhibitors (SSRIs) has an effect on depression and associated symptoms in people with Borderline Personality Disorder (BPD). SSRIs are often prescribed to patients with BPD, but their specific effects on depression and related symptoms, including self-harm, in people with BPD require further study. In this study, an FDA approved SSRI will be compared to a placebo in order to determine the effects of the medication.

The study will last 5 months, and involves 13 visits.

Part of the study involves taking an experimental drug or a placebo.

You will receive a confidential evaluation to see if you qualify to enter the study. If you qualify, you will then receive a full behavioral assessment.

Eligible individuals will be compensated up to $280 for completing the study.

Eligibility

  • Have problems with mood swings, fear of being abandoned, unstable relationships, unstable sense of identity, irritability or anxiety, chronic feelings of emptiness, or dangerous, impulsive behavior.

  • Experience feelings of sadness, worthlessness, hopelessness, lack of energy, changes in sleep pattern.

  • Be between the ages of 18 and 40.

  • Meet other eligibility requirements as outlined by the research protocol.

    Duration

    13 visits over 5 months

    Compensation

    Up to $280.

    Contact

    Laurel Couture
    773-834-8984
    SSRIBPD@bsd.uchicago.edu